BG108125A - Peg-конюгати на хепатоцитния растежен фактор (hgt-nk4) - Google Patents

Peg-конюгати на хепатоцитния растежен фактор (hgt-nk4) Download PDF

Info

Publication number: BG108125A
Authority: BG; Bulgaria
Prior art keywords: peg; kda; group; molecular weight; polyethylene glycol
Prior art date: 2001-02-23

Application number

BG108125A

Other languages

Bulgarian (bg)

English (en)

Inventor

Michael Brandt

Apollon Papadimitriou

Original Assignee

F.Hoffmann-La Roche Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-23

Filing date

2003-08-22

Publication date

2004-09-30

2003-08-22 Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag

2004-09-30 Publication of BG108125A publication Critical patent/BG108125A/bg

Links

108090000100 Hepatocyte Growth Factor Proteins 0.000 title claims abstract description 16
102000003745 Hepatocyte Growth Factor Human genes 0.000 title claims description 15
229920001223 polyethylene glycol Polymers 0.000 claims abstract description 132
102100021866 Hepatocyte growth factor Human genes 0.000 claims abstract description 29
239000002202 Polyethylene glycol Substances 0.000 claims abstract description 14
206010028980 Neoplasm Diseases 0.000 claims abstract description 13
125000003827 glycol group Chemical group 0.000 claims abstract description 8
239000003814 drug Substances 0.000 claims abstract description 4
210000004898 n-terminal fragment Anatomy 0.000 claims abstract 4
238000000034 method Methods 0.000 claims description 26
238000002360 preparation method Methods 0.000 claims description 20
125000003277 amino group Chemical group 0.000 claims description 18
239000008194 pharmaceutical composition Substances 0.000 claims description 14
201000011510 cancer Diseases 0.000 claims description 8
239000003937 drug carrier Substances 0.000 claims description 3
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
229940124597 therapeutic agent Drugs 0.000 abstract 1
101000998139 Homo sapiens Interleukin-32 Proteins 0.000 description 147
235000018102 proteins Nutrition 0.000 description 34
102000004169 proteins and genes Human genes 0.000 description 34
108090000623 proteins and genes Proteins 0.000 description 34
101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 28
101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 25
101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 25
230000006320 pegylation Effects 0.000 description 21
238000006243 chemical reaction Methods 0.000 description 20
108090000765 processed proteins & peptides Proteins 0.000 description 20
239000003153 chemical reaction reagent Substances 0.000 description 19
230000000694 effects Effects 0.000 description 17
102000004196 processed proteins & peptides Human genes 0.000 description 17
235000001014 amino acid Nutrition 0.000 description 16
229940024606 amino acid Drugs 0.000 description 16
229920001184 polypeptide Polymers 0.000 description 16
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 16
150000001413 amino acids Chemical class 0.000 description 13
239000000203 mixture Substances 0.000 description 12
125000000217 alkyl group Chemical group 0.000 description 11
-1 glycerol Chemical class 0.000 description 11
230000005764 inhibitory process Effects 0.000 description 11
229920000642 polymer Polymers 0.000 description 11
239000004472 Lysine Substances 0.000 description 10
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 10
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
241000894007 species Species 0.000 description 10
210000004027 cell Anatomy 0.000 description 9
238000002474 experimental method Methods 0.000 description 9
229910000160 potassium phosphate Inorganic materials 0.000 description 8
235000011009 potassium phosphates Nutrition 0.000 description 8
230000035755 proliferation Effects 0.000 description 8
125000006239 protecting group Chemical group 0.000 description 8
125000003396 thiol group Chemical group [H]S* 0.000 description 8
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
239000003431 cross linking reagent Substances 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
238000000926 separation method Methods 0.000 description 6
206010027476 Metastases Diseases 0.000 description 5
239000007853 buffer solution Substances 0.000 description 5
238000005859 coupling reaction Methods 0.000 description 5
235000018417 cysteine Nutrition 0.000 description 5
238000002270 exclusion chromatography Methods 0.000 description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
230000004048 modification Effects 0.000 description 5
238000012986 modification Methods 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
239000000243 solution Substances 0.000 description 5
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
102000004889 Interleukin-6 Human genes 0.000 description 4
108090001005 Interleukin-6 Proteins 0.000 description 4
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
229930195725 Mannitol Natural products 0.000 description 4
241001415846 Procellariidae Species 0.000 description 4
108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
238000003776 cleavage reaction Methods 0.000 description 4
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
238000010828 elution Methods 0.000 description 4
230000005714 functional activity Effects 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
229940100601 interleukin-6 Drugs 0.000 description 4
239000000594 mannitol Substances 0.000 description 4
235000010355 mannitol Nutrition 0.000 description 4
239000000047 product Substances 0.000 description 4
238000000746 purification Methods 0.000 description 4
238000004366 reverse phase liquid chromatography Methods 0.000 description 4
230000007017 scission Effects 0.000 description 4
239000001488 sodium phosphate Substances 0.000 description 4
229910000162 sodium phosphate Inorganic materials 0.000 description 4
230000006641 stabilisation Effects 0.000 description 4
238000011105 stabilization Methods 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 4
230000004614 tumor growth Effects 0.000 description 4
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
108010053070 Glutathione Disulfide Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
108090000288 Glycoproteins Proteins 0.000 description 3
102000003886 Glycoproteins Human genes 0.000 description 3
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
230000004913 activation Effects 0.000 description 3
125000003275 alpha amino acid group Chemical group 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
230000000875 corresponding effect Effects 0.000 description 3
230000008878 coupling Effects 0.000 description 3
238000010168 coupling process Methods 0.000 description 3
HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 3
238000009472 formulation Methods 0.000 description 3
YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 3
229960002897 heparin Drugs 0.000 description 3
229920000669 heparin Polymers 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
239000002054 inoculum Substances 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
SEEYREPSKCQBBF-UHFFFAOYSA-N n-methylmaleimide Chemical compound CN1C(=O)C=CC1=O SEEYREPSKCQBBF-UHFFFAOYSA-N 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
230000001766 physiological effect Effects 0.000 description 3
229920001993 poloxamer 188 Polymers 0.000 description 3
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
229920000053 polysorbate 80 Polymers 0.000 description 3
230000035484 reaction time Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
150000003573 thiols Chemical group 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
239000004475 Arginine Substances 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
239000012505 Superdex™ Substances 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000009471 action Effects 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
239000012062 aqueous buffer Substances 0.000 description 2
229960003121 arginine Drugs 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
230000001588 bifunctional effect Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
239000003599 detergent Substances 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000012634 fragment Substances 0.000 description 2
150000002334 glycols Chemical class 0.000 description 2
102000057308 human HGF Human genes 0.000 description 2
230000002637 immunotoxin Effects 0.000 description 2
229940051026 immunotoxin Drugs 0.000 description 2
239000002596 immunotoxin Substances 0.000 description 2
231100000608 immunotoxin Toxicity 0.000 description 2
239000012535 impurity Substances 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
230000009545 invasion Effects 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
229920001427 mPEG Polymers 0.000 description 2
239000000463 material Substances 0.000 description 2
230000009401 metastasis Effects 0.000 description 2
230000005012 migration Effects 0.000 description 2
238000013508 migration Methods 0.000 description 2
230000002297 mitogenic effect Effects 0.000 description 2
210000000496 pancreas Anatomy 0.000 description 2
230000035515 penetration Effects 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
239000000902 placebo Substances 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
239000008057 potassium phosphate buffer Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
230000005747 tumor angiogenesis Effects 0.000 description 2
VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
WQUWKZJWBCOHQH-UHFFFAOYSA-N 1-[2-[2-(2-methoxyethoxy)ethoxy]ethyl]pyrrole-2,5-dione Chemical compound COCCOCCOCCN1C(=O)C=CC1=O WQUWKZJWBCOHQH-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
241000282412 Homo Species 0.000 description 1
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
108010047761 Interferon-alpha Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
102000004890 Interleukin-8 Human genes 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
206010027457 Metastases to liver Diseases 0.000 description 1
208000007696 Multicystic Dysplastic Kidney Diseases 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
102000016387 Pancreatic elastase Human genes 0.000 description 1
108010067372 Pancreatic elastase Proteins 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
101100230982 Rattus norvegicus Hgf gene Proteins 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
125000003368 amide group Chemical group 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229940121369 angiogenesis inhibitor Drugs 0.000 description 1
239000004037 angiogenesis inhibitor Substances 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000001772 anti-angiogenic effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
229960003589 arginine hydrochloride Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
239000002981 blocking agent Substances 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
150000004648 butanoic acid derivatives Chemical class 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
125000001589 carboacyl group Chemical group 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000004709 cell invasion Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
125000003636 chemical group Chemical group 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 1
229940099500 cystamine Drugs 0.000 description 1
150000001945 cysteines Chemical class 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
125000002228 disulfide group Chemical group 0.000 description 1
150000002019 disulfides Chemical class 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
102000046616 human IL32 Human genes 0.000 description 1
229910052588 hydroxylapatite Inorganic materials 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
229940096397 interleukin-8 Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
210000002429 large intestine Anatomy 0.000 description 1
239000002502 liposome Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
230000004899 motility Effects 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
230000007170 pathology Effects 0.000 description 1
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229950008882 polysorbate Drugs 0.000 description 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
239000002243 precursor Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000008569 process Effects 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
239000000523 sample Substances 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
238000011272 standard treatment Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000003774 sulfhydryl reagent Substances 0.000 description 1
150000003459 sulfonic acid esters Chemical class 0.000 description 1
150000003460 sulfonic acids Chemical class 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
239000012588 trypsin Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Oncology (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BG108125A 2001-02-23 2003-08-22 Peg-конюгати на хепатоцитния растежен фактор (hgt-nk4) BG108125A (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP01104640A EP1234583A1 (en)	2001-02-23	2001-02-23	PEG-conjugates of HGF-NK4
PCT/EP2002/001837 WO2002074344A2 (en)	2001-02-23	2002-02-21	Peg-conjugates of hgt-nk4

Publications (1)

Publication Number	Publication Date
BG108125A true BG108125A (bg)	2004-09-30

Family

ID=8176596

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG108125A BG108125A (bg)	2001-02-23	2003-08-22	Peg-конюгати на хепатоцитния растежен фактор (hgt-nk4)

Country Status (27)

Country	Link
US (2)	US20030012775A1 (cs)
EP (2)	EP1234583A1 (cs)
JP (2)	JP2004521139A (cs)
KR (2)	KR20030072629A (cs)
CN (1)	CN100339393C (cs)
AR (1)	AR032574A1 (cs)
AU (1)	AU2002233354B2 (cs)
BG (1)	BG108125A (cs)
BR (1)	BR0207510A (cs)
CA (1)	CA2438308A1 (cs)
CZ (1)	CZ20032511A3 (cs)
EC (1)	ECSP034741A (cs)
GT (1)	GT200200038A (cs)
HR (1)	HRP20030659A2 (cs)
HU (1)	HUP0400979A2 (cs)
IL (1)	IL157426A0 (cs)
MA (1)	MA26998A1 (cs)
MX (1)	MXPA03007130A (cs)
NO (1)	NO20033737L (cs)
PA (1)	PA8540501A1 (cs)
PE (1)	PE20020992A1 (cs)
PL (1)	PL367402A1 (cs)
RU (1)	RU2293574C2 (cs)
SK (1)	SK11652003A3 (cs)
WO (1)	WO2002074344A2 (cs)
YU (1)	YU65103A (cs)
ZA (1)	ZA200306080B (cs)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2003270118A1 (en) *	2002-08-30	2004-03-19	F. Hoffmann-La Roche Ag	Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
WO2004085471A2 (en) *	2003-03-24	2004-10-07	Novo Nordisk A/S	Glp-2 derivatives
JP2007525981A (ja)	2004-03-03	2007-09-13	エフ．ホフマン−ラ　ロシュ　アーゲー	肝細胞成長因子のｎ末端フラグメントを組み換え発現するための方法
JP4511589B2 (ja)	2004-03-03	2010-07-28	エフ．ホフマン−ラロシュアーゲー	肝細胞成長因子のｎ末端フラグメントを精製するための方法
US20090202606A1 (en) *	2008-01-25	2009-08-13	Viromed Co., Ltd.	Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
JP5579164B2 (ja) *	2008-04-09	2014-08-27	ビロメッドカンパニー，リミテッド	凍結乾燥ｄｎａ製剤、組成物、及び凍結乾燥ｄｎａ製剤を製造する方法
CN102399293B (zh) *	2008-06-03	2013-12-04	中国科学院遗传与发育生物学研究所	一种与纤维蛋白特异结合的重组蛋白及其应用
US10532020B2 (en)	2012-08-22	2020-01-14	Revlon Consumer Products Corporation	Nail coatings having enhanced adhesion
MX2015014438A (es)	2013-04-18	2016-05-18	Armo Biosciences Inc	Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
EP3010527B1 (en)	2013-06-17	2018-08-08	Armo Biosciences, Inc.	Method for assessing protein identity and stability
CN105658232A (zh)	2013-08-30	2016-06-08	阿尔莫生物科技股份有限公司	使用白细胞介素-10治疗疾病和病症的方法
CN120242030A (zh)	2013-11-11	2025-07-04	阿尔莫生物科技股份有限公司	将白细胞介素-10用于治疗疾病和病症的方法
WO2015187295A2 (en)	2014-06-02	2015-12-10	Armo Biosciences, Inc.	Methods of lowering serum cholesterol
WO2016060996A2 (en)	2014-10-14	2016-04-21	Armo Biosciences, Inc.	Interleukin-15 compositions and uses thereof
AU2015336101A1 (en)	2014-10-22	2017-04-20	Armo Biosciences, Inc.	Methods of using interleukin-10 for treating diseases and disorders
WO2016126615A1 (en)	2015-02-03	2016-08-11	Armo Biosciences, Inc.	Methods of using interleukin-10 for treating diseases and disorders
US20160361415A1 (en)	2015-05-28	2016-12-15	Armo Biosciences, Inc.	Methods of Using Interleukin-10 for Treating Diseases and Disorders
KR20180038553A (ko)	2015-08-25	2018-04-16	아르모 바이오사이언시스 인코포레이티드	질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
JPWO2020158690A1 (ja) *	2019-01-28	2021-12-16	東レ株式会社	肝細胞増殖因子又はその活性断片のポリエチレングリコール修飾体
BR112021012472A2 (pt) *	2019-01-28	2021-11-30	Toray Industries	Forma modificada por polietileno glicol de um fator de crescimento de hepatócito ou um fragmento ativo do mesmo, e, medicamento

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE222603T1 (de)	1992-05-18	2002-09-15	Genentech Inc	Hepatozytwachstumfaktor variante
US6472178B1 (en)	1998-02-27	2002-10-29	Regeneron Pharmaceuticals, Inc.	Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
GB9225448D0 (en) *	1992-12-04	1993-01-27	Erba Carlo Spa	Improved synthesis of polymer bioactive conjugates
GEP20002180B (en) *	1994-03-31	2000-07-25	Amgen Inc	Composition and Methods for Stimulating Megakaryocyte Growth and Differentiation
RU2158603C2 (ru) *	1994-05-31	2000-11-10	Амген Инк.	Способы и препараты для стимулирования роста и дифференцировки мегакариоцитов
US5824784A (en) *	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
US5770577A (en) *	1994-11-14	1998-06-23	Amgen Inc.	BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
EP0816381B1 (en) *	1995-03-10	2004-01-14	NAKAMURA, Toshikazu	Polyethylene glycol modified hepatocyte growth factor (hgf)
ES2093593T1 (es) *	1995-05-05	1997-01-01	Hoffmann La Roche	Proteinas obesas (ob) recombinantes.
US6025324A (en) *	1996-05-15	2000-02-15	Hoffmann-La Roche Inc.	Pegylated obese (ob) protein compositions
ATE342729T1 (de)	1997-01-15	2006-11-15	Phoenix Pharmacologics Inc	Modifizierter tumor-nekrosefaktor
US6133426A (en) *	1997-02-21	2000-10-17	Genentech, Inc.	Humanized anti-IL-8 monoclonal antibodies
EP0922446A1 (en) *	1997-12-03	1999-06-16	Applied Research Systems Ars Holding N.V.	Solution-phase site-specific preparation of GRF-PEG conjugates
EE05214B1 (et) *	1998-04-28	2009-10-15	Applied Research Systems ARS Holding N.V.	Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon
US6420339B1 (en) *	1998-10-14	2002-07-16	Amgen Inc.	Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
CZ299516B6 (cs) *	1999-07-02	2008-08-20	F. Hoffmann-La Roche Ag	Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
JO2291B1 (en) *	1999-07-02	2005-09-12	اف . هوفمان لاروش ايه جي	Erythropoietin derivatives
US6586398B1 (en) *	2000-04-07	2003-07-01	Amgen, Inc.	Chemically modified novel erythropoietin stimulating protein compositions and methods
AU2002233230B2 (en) *	2000-12-20	2007-02-01	F. Hoffmann-La Roche Ag	Erythropoietin conjugates

2001
- 2001-02-23 EP EP01104640A patent/EP1234583A1/en not_active Withdrawn
2002
- 2002-02-20 PA PA20028540501A patent/PA8540501A1/es unknown
- 2002-02-20 PE PE2002000144A patent/PE20020992A1/es not_active Application Discontinuation
- 2002-02-21 SK SK1165-2003A patent/SK11652003A3/sk unknown
- 2002-02-21 BR BR0207510-5A patent/BR0207510A/pt not_active IP Right Cessation
- 2002-02-21 KR KR10-2003-7010748A patent/KR20030072629A/ko not_active Ceased
- 2002-02-21 WO PCT/EP2002/001837 patent/WO2002074344A2/en not_active Ceased
- 2002-02-21 HU HU0400979A patent/HUP0400979A2/hu unknown
- 2002-02-21 CZ CZ20032511A patent/CZ20032511A3/cs unknown
- 2002-02-21 MX MXPA03007130A patent/MXPA03007130A/es not_active Application Discontinuation
- 2002-02-21 AR ARP020100593A patent/AR032574A1/es not_active Application Discontinuation
- 2002-02-21 EP EP02700263A patent/EP1389132A2/en not_active Withdrawn
- 2002-02-21 HR HR20030659A patent/HRP20030659A2/hr not_active Application Discontinuation
- 2002-02-21 IL IL15742602A patent/IL157426A0/xx unknown
- 2002-02-21 PL PL02367402A patent/PL367402A1/xx not_active Application Discontinuation
- 2002-02-21 US US10/081,309 patent/US20030012775A1/en not_active Abandoned
- 2002-02-21 JP JP2002573051A patent/JP2004521139A/ja not_active Withdrawn
- 2002-02-21 CN CNB028052951A patent/CN100339393C/zh not_active Expired - Fee Related
- 2002-02-21 AU AU2002233354A patent/AU2002233354B2/en not_active Ceased
- 2002-02-21 YU YU65103A patent/YU65103A/sh unknown
- 2002-02-21 RU RU2003127395/15A patent/RU2293574C2/ru not_active IP Right Cessation
- 2002-02-21 KR KR1020097002234A patent/KR20090020713A/ko not_active Ceased
- 2002-02-21 CA CA002438308A patent/CA2438308A1/en not_active Abandoned
- 2002-02-22 GT GT200200038A patent/GT200200038A/es unknown
2003
- 2003-08-06 ZA ZA200306080A patent/ZA200306080B/en unknown
- 2003-08-19 MA MA27285A patent/MA26998A1/fr unknown
- 2003-08-21 EC EC2003004741A patent/ECSP034741A/es unknown
- 2003-08-22 NO NO20033737A patent/NO20033737L/no not_active Application Discontinuation
- 2003-08-22 BG BG108125A patent/BG108125A/bg unknown
2007
- 2007-10-10 US US11/869,797 patent/US7846896B2/en not_active Expired - Lifetime
2010
- 2010-04-22 JP JP2010099120A patent/JP2010174034A/ja active Pending

Also Published As

Publication number	Publication date
BR0207510A (pt)	2004-07-27
ECSP034741A (es)	2003-10-28
EP1234583A1 (en)	2002-08-28
HRP20030659A2 (en)	2004-08-31
HUP0400979A2 (hu)	2004-08-30
RU2003127395A (ru)	2005-03-20
MA26998A1 (fr)	2004-12-20
ZA200306080B (en)	2004-11-23
CZ20032511A3 (en)	2004-03-17
CN1571679A (zh)	2005-01-26
MXPA03007130A (es)	2003-11-18
CA2438308A1 (en)	2002-09-26
PL367402A1 (en)	2005-02-21
JP2010174034A (ja)	2010-08-12
US20030012775A1 (en)	2003-01-16
EP1389132A2 (en)	2004-02-18
NO20033737D0 (no)	2003-08-22
SK11652003A3 (sk)	2004-05-04
CN100339393C (zh)	2007-09-26
US20080085857A1 (en)	2008-04-10
RU2293574C2 (ru)	2007-02-20
JP2004521139A (ja)	2004-07-15
KR20030072629A (ko)	2003-09-15
GT200200038A (es)	2002-09-30
IL157426A0 (en)	2004-03-28
PA8540501A1 (es)	2002-09-30
WO2002074344A2 (en)	2002-09-26
YU65103A (sh)	2006-03-03
US7846896B2 (en)	2010-12-07
AR032574A1 (es)	2003-11-12
NO20033737L (no)	2003-10-21
PE20020992A1 (es)	2002-11-01
KR20090020713A (ko)	2009-02-26
AU2002233354B2 (en)	2006-11-30
WO2002074344A3 (en)	2003-12-04

Publication	Publication Date	Title
US7846896B2 (en)	2010-12-07	PEG conjugates of NK4
EP1267942B1 (en)	2011-05-25	Chemically modified novel erythropoietin stimulating protein compositions and methods
ES2866674T3 (es)	2021-10-19	Conjugados de una fracción de IL-2 y un polímero
JP4753867B2 (ja)	2011-08-24	ヒトｉｌ−１８を含むコンジュゲートおよびその置換変異体
CA2942571C (en)	2023-09-19	Conjugates of an il-15 moiety and a polymer
AU2002233354A1 (en)	2003-03-27	PEG-conjugates of HGT-NK4
US8901277B2 (en)	2014-12-02	Interferon alpha mutant and its polyethylene glycol derivative
ES2460671T3 (es)	2014-05-14	Uso de eritropoyetina en el tratamiento de alteraciones de la distribución del hierro en enfermedades intestinales inflamatorias crónicas
AU2001255256A1 (en)	2002-01-10	Chemically modified novel erythropoietin stimulating protein compositions and methods
US20130195799A1 (en)	2013-08-01	Synergistic biomolecule-polymer conjugates
BRPI0614257A2 (pt)	2011-03-15	conjugados de uma porção de g-csf e um polìmero
US20070166278A1 (en)	2007-07-19	Novel g-csf conjugates
ES2386575T3 (es)	2012-08-23	Interferón alfa 2a modificado por polietilenglicol, su proceso de síntesis y su aplicación
US20040110685A1 (en)	2004-06-10	Scatter factor/hepatocyte growth factor antagonist NK4 for the treatment of glioma
KR101104574B1 (ko)	2012-01-11	폴리에틸렌글리콜로 화학적으로 수식된 인간 성장 호르몬, 이의 제조방법 및 용도